α-Amylase-IN-13

α-Amylase-IN-13 is an orally active, selective, brain-penetrant α-amylase inhibitor (IC50 = 0.71 μM) . α-Amylase-IN-13 inhibits α-amylase through a mixed type of inhibition mechanism. α-Amylase-IN-13 leads to a significant reduction in blood glucose level in diabetic rats. α-Amylase-IN-13 causes significant histopathological improvements in the kidney, liver, and pancreas. α-Amylase-IN-13 can be used for the study of diabetic complications[1].

Product Specifications

CAS Number

[3085413-64-2]

UNSPSC

12352005

Target

Amylases

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Endocrinology; Metabolic Disease

Smiles

O=C(NC1=CC=C(C(F)(F)F)C=C1)CN(C/2=O)C(SC2=C/C3=NC=CN3C)=S

Molecular Formula

C17H13F3N4O2S2

Molecular Weight

426.44

References & Citations

[1]Ravi A, et al. Synthesis, in vitro and in vivo evaluation, and computational modeling analysis of thioxothiazolidine derivatives as highly potent and selective α-amylase inhibitors. Eur J Med Chem. 2025 Jul 5;291:117584.